|
Therapy Area
Treatment of hepatitis C virus (HCV) infection.
|
|
Phase
Phase I studies completed and reported. Phase IIa studies in patients are ongoing. |
Competitive Edge
Novel HCV NS3/4A protease inhibitor with excellent antiviral activity in the replicon cell-based assay. Good oral bioavailability. |
Project data
- Collaboration with Tibotec since 2004
- Phase IIa studies ongoing
- Excellent antiviral activity in cellbased assays
- Very good oral bioavailability
- Several series of potent inhibitors have been developed that provide backups
|
Main products 2006
Pegintron (Peg-IFN) Schering-Plough
Intron A (IFN) Schering-Plough
Rebetol (Ribavirin) Schering-Plough
Pegasys (Peg-IFN) Roche
Copegus (Ribavirin) Roche
|
|
|
|
|
